Only 29% of People With Diabetes Report That Their Doctors ask Them for Input for Their own Treatment Plans

Melbourne, Australia (ots/PRNewswire) -

Results from the global Diabetes Attitudes, Wishes and Needs 2
study (DAWN2(TM)) presented today at a symposium during the World
Diabetes Congress of the International Diabetes Federation (IDF),
show that only 29% of people with diabetes report that their
healthcare team ask for their input when making their treatment
plans. Furthermore, only 33% said they were encouraged by their
healthcare professional to ask questions in the consultation.

These results are surprising, given the importance of active
involvement of people with diabetes in their own treatment and care.
In fact, 84% of healthcare professionals who took part in the study
said it would be helpful if their patients prepared questions in
advance of the consultation[1].

To view the Multimedia News Release, please click:

http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doct
or-treatment

"People with diabetes who feel supported and capable of
self-managing their condition are more likely to have a successful
treatment outcome and therefore have the opportunity to live a better
life with diabetes," explained Ingrid Willaing, head of Education
Research at the Steno Diabetes Center and lead national investigator
for DAWN2(TM) in Denmark, during her symposium presentation. "The
DAWN2(TM) study highlights that far too few people with diabetes are
supported to take an active role".

To help break down communication barriers and misconceptions about
diabetes treatments and thereby improve effective self-management of
type 2 diabetes,a theatre play called "Getting Straight to the Point"
was held at the Congress on 4 December. Here, a panel of leading
diabetes experts called for both healthcare professionals and people
with type 2 diabetes to create opportunities for open dialogue,
shared decision-making and active engagement for better physical and
emotional outcomes.

A series of other global DAWN2(TM) results were announced during
the Congress highlighting the insufficiencies relating to quality of
life with diabetes, support for families, access to diabetes
education and psychosocial support, positive awareness of diabetes in
society and attention to the special needs of vulnerable populations
with diabetes.

"The DAWN2(TM) study calls for united efforts across stakeholders
and nations to advance a person-centredapproach to improve
prevention, care, education and support for people with diabetes and
their families," says Sir Michael Hirst, president of the
International Diabetes Federation.

DAWN2(TM) represents the voices of more than 15,000 people with
diabetes, their family members and healthcare professionals in 17
countries across 4 continents.

About DAWN2(TM)

DAWN2(TM) is a global Novo Nordisk initiative conducted in
collaboration with the IDF, the International Alliance of Patients'
Organizations (IAPO), the Steno Diabetes Center and a range of other
national, regional and global partners. The DAWN2(TM) results
highlight opportunities for improving diabetes care, education and
community support by putting people with diabetes and their families
centre stage. The DAWN2(TM) study will be used internationally and
nationally to facilitate dialogue among patient organisations,
healthcare professionals and other key stakeholders to develop action
plans for improvement of the lives of people with diabetes. Further
information is available at http://www.dawnstudy.com.

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare
company with 90 years of innovation and leadership in diabetes care.
The company also has leading positions within haemophilia care,
growth hormone therapy and hormone replacement therapy. Novo Nordisk
employs approximately 37,000 employees in 75 countries, and markets
its products in more than 180 countries. For more information, visit
novonordisk.com.

Further information

Media:
Daniel Vamosi Martinussen
+45-3079-1879
dvmm@novonordisk.com

Ken Inchausti (US)
+1-609-514-8316
kiau@novonordisk.com

Investors:
Kasper Roseeuw Poulsen
+45-4442-4303
krop@novonordisk.com

Frank Daniel Mersebach
+45-4442-0604
fdni@novonordisk.com

Daniel Bohsen
+45-3079-6376
dabo@novonordisk.com

Lars Borup Jacobsen
+45-3075-3479
lbpj@novonordisk.com

Jannick Lindegaard (US)
+1-609-786-4575
jlis@novonordisk.com

References

1. I. Willaing, DAWN2(TM) Study Results: Involvement and
Education. Oral Lecture, DAWN2(TM) Symposium, 5 December 2013, World
Diabetes Congress of the International Diabetes Federation (IDF).

Video:
http://www.multivu.com/mnr/64152-novo-nordisk-diabetes-report-doctor-treatment

ots Originaltext: Novo Nordisk, DAWN2TM, International Diabetes Federation, Steno Diabetes Center
Im Internet recherchierbar: http://www.presseportal.de